Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 4OTHER 3NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neoplasms 66Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 48Prostatic Neoplasms 46Lung Neoplasms 46Leukemia, Myeloid, Acute 39Ovarian Neoplasms 38Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 28Glioma 28Lymphoma, Non-Hodgkin 26Sarcoma 25Urinary Bladder Neoplasms 24Carcinoma, Renal Cell 24Brain Neoplasms 24Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Leukemia, Lymphocytic, Chronic, B-Cell 18Stomach Neoplasms 17Small Cell Lung Carcinoma 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16Glioblastoma 16

Interventions

olaparib 1lutetium Lu 177 dotatate 1fluorodopa F 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoid Tumor × 90 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT00646022 2026-05-12

Natural History of Familial Carcinoid Tumor

National Institutes of Health Clinical Center (CC)

Recruiting
1,600 enrolled
Endocrine

Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡